Discover and read the best of Twitter Threads about #sdm
Most recents (8)
New paper for ‘ibis.iSDM’ now published in Ecological Informatics. Here I present a new R-package that allows the integration of different datatypes in SDMs. But it can do much more than that... #sdm #biodiversity #conservation
doi.org/10.1016/j.ecoi…
👇(1/8)
doi.org/10.1016/j.ecoi…
👇(1/8)
So one might ask why another R-package for correlative SDMs, and I generally agree. The specific role of the package for me and our group is to a) support all types of integration originally highlighted by Fletcher et al. and more (doi.org/10.1002/ecy.27…, @FletcherEcology) (2/8)
..., b) propose a modelling framework founded in Poisson Process Models and support Bayesian SDMs, c) enable easy construction of scenarios and projections and d) have a modular coding framework that can be easily updated with further functionalities (3/8)
#aha22 - SPORT trial
💊nutraceuticals ubiquitous and “assumed” by many pts to be heart healthy.
💊💰💸industry
💊 SPORT ➡️ compared to rosuva and placebo, do they impact biomarkers?
jacc.org/doi/abs/10.101…
@kewatson @ErinMichos @ljlaffin 1/
💊nutraceuticals ubiquitous and “assumed” by many pts to be heart healthy.
💊💰💸industry
💊 SPORT ➡️ compared to rosuva and placebo, do they impact biomarkers?
jacc.org/doi/abs/10.101…
@kewatson @ErinMichos @ljlaffin 1/
N=199, randomized single blind
💊 lipid, hsCRP, CMP. Baseline and at 28 days.
💊 1° risk, age 40-75, LDL-C 70-189, borderline to upper intermediate risk (5-20%, estimated 10 yr event)
💊 1° endpt: %LDL-C change vs rosuva
💊2° endpt: biomarkers vs rosuva; vs placebo
#aha22 2/
💊 lipid, hsCRP, CMP. Baseline and at 28 days.
💊 1° risk, age 40-75, LDL-C 70-189, borderline to upper intermediate risk (5-20%, estimated 10 yr event)
💊 1° endpt: %LDL-C change vs rosuva
💊2° endpt: biomarkers vs rosuva; vs placebo
#aha22 2/
💊 most were at least 7.5% 10 year risk
💊 nice representation of 💃🏽
💊 LDL-C >100 (~125); hsCRP <2.0
#aha22 3/
💊 nice representation of 💃🏽
💊 LDL-C >100 (~125); hsCRP <2.0
#aha22 3/
#AFib is the most common sustained heart rhythm problem in the world. 🌎
#AFib increases the risk of #stroke & #heartfailure. It causes symptoms like fatigue, dizziness & shortness of breath and can reduce patients’ quality of life.
Offering #dialysis to patients with a new diagnosis of #malignancy is always an emotive and complex affair if they present with an #AKI or #renaldysfunction
Sometimes it’s pretty clear - like in the 30 something who presents with a cervical cancer , bilateral hydronephrosis and K of 7- one will usually explain to The patient what’s the issue and buy them time for intervention which buys time for an oncology consult and further mx
#Artikel6: Können wir in Glasgow den Sack endlich zu machen? Eine Halbzeiteinschätzung zur Hausaufgabenerfüllung auf der #COP26.
1/ Die Hausaufgabe der #COP26 besteht darin, eine Lösung für das seit vier Jahren verschleppte Problem des internationalen Emissionshandels zu lösen. Denn daran hängt der in vielfältiger Weise der Abschluss des gesamten Regelwerks zur Umsetzung des Pariser Übereinkommens.
2/Das Problem ist vertrackt und geht auch in Glasgow aktuell nur schleppend voran. Von einem entscheidungsreifen Dokument sind die Verhandler*innen noch meilenweit entfernt. Trotzdem habe ich Hoffnung auf eine Lösung in Glasgow, wie ich hier darlegen möchte.
Do doctors understand how well treatments work?
We asked >500 clinicians in 8 US states
Chance that common treatments help an individual patient with
atrial fibrillation
hypertension
high cholesterol
osteoporosis
Open access: ja.ma/3A1u7N4 via @JAMANetwork
1/🧵
We asked >500 clinicians in 8 US states
Chance that common treatments help an individual patient with
atrial fibrillation
hypertension
high cholesterol
osteoporosis
Open access: ja.ma/3A1u7N4 via @JAMANetwork
1/🧵
Recently we examined clinician understanding of probability in DIAGNOSIS
The current question was similar but for TREATMENT
In the works, are numeracy, acceptance of uncertainty and other clinician personality factors associated with decisions?
2/🧵
The current question was similar but for TREATMENT
In the works, are numeracy, acceptance of uncertainty and other clinician personality factors associated with decisions?
2/🧵
Appreciate past interest from @tylercowen on probability in diagnosis.
In some ways, economists like him and @profemilyoster or statisticians like @natesilver538 have a better framework than doctors for assessing real life data, risk and tradeoffs
marginalrevolution.com/marginalrevolu…
3/🧵
In some ways, economists like him and @profemilyoster or statisticians like @natesilver538 have a better framework than doctors for assessing real life data, risk and tradeoffs
marginalrevolution.com/marginalrevolu…
3/🧵
How good are doctors at diagnosis?
This is the most relevant paper I have written. Not perfect but addresses a huge issue I think could change medicine if acknowledged
…it has changed how I think about diagnosis
ja.ma/3rQNtjv
@JAMAInternalMed
@drjohnm
1/n
This is the most relevant paper I have written. Not perfect but addresses a huge issue I think could change medicine if acknowledged
…it has changed how I think about diagnosis
ja.ma/3rQNtjv
@JAMAInternalMed
@drjohnm
1/n
summary:
Clinicians widely overestimated chance of disease especially after testing
Cardiac ischemia after + ECG—EBM 2-11%, median answer 70%
UTI after + urine cx—EBM 0-8.3%, answer 80%
Breast CA after + mammo—EBM 3-9%, answer 50%
Pneumonia after + CXR EBM 46-65%, answer 95%
Clinicians widely overestimated chance of disease especially after testing
Cardiac ischemia after + ECG—EBM 2-11%, median answer 70%
UTI after + urine cx—EBM 0-8.3%, answer 80%
Breast CA after + mammo—EBM 3-9%, answer 50%
Pneumonia after + CXR EBM 46-65%, answer 95%
Gerd Gigerenzer, David Eddy, @StevenWoloshin @arjunmanrai & others asked how well doctors do at the math of understanding diagnosis, and found they aren’t great.
Many of issues w/ real life tests covered by @deeksj @d_spiegel @dan_diekema
Many of issues w/ real life tests covered by @deeksj @d_spiegel @dan_diekema
Debate CAC vs CTA in primary prevention?
I will start with a provocative statement
Screening, foundational strategy for decades in prev cardio is a seductive paradigm
Its so 1990’s
We are barking on the wrong tree
In 2020, I will explain why this strategy is a fallacy
#ASPC2020
I will start with a provocative statement
Screening, foundational strategy for decades in prev cardio is a seductive paradigm
Its so 1990’s
We are barking on the wrong tree
In 2020, I will explain why this strategy is a fallacy
#ASPC2020
#1 Both primary and secondary prevention lower disease burden and outcomes
#2 Marginal benefit of extensive screening
#3 Whats left to screen? Majority already treatment candidates
#4 Our stakeholders asking for "derisking" vs "screening"
#APSC2020
#2 Marginal benefit of extensive screening
#3 Whats left to screen? Majority already treatment candidates
#4 Our stakeholders asking for "derisking" vs "screening"
#APSC2020
-Despite being being an avid advocate of CAC screening in past, it was time to move on
-Showed 1 in 2 statin candidates have #PowerOfZero
-Proposed CAC as SDM tool
-Concept confirmed in 3 other cohorts, better than any neg marker, cost-effective, and no statin treatment benefit
-Showed 1 in 2 statin candidates have #PowerOfZero
-Proposed CAC as SDM tool
-Concept confirmed in 3 other cohorts, better than any neg marker, cost-effective, and no statin treatment benefit
